Complications of subspecialty ophthalmic care: Endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications

Luis Haddock, David J. Ramsey, Lucy H. Young

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

The use of medications directed against vascular endothelial growth factor (VEGF) signaling has revolutionized the treatment of age-related macular degeneration (AMD) and many other retinal diseases in the last decade. However, the rapidly increasing use of these agents has led to a rise in treatment-Associated complications. One of the most feared by patients and ophthalmologists is post-injection endophthalmitis, which can result in severe vision loss and, in rare cases, loss of the eye. The aim of this article is to review the incidence, clinical findings, risk factors, management, and visual outcomes in cases of endophthalmitis following intravitreal injections of anti-VEGF medications.

Original languageEnglish (US)
Pages (from-to)257-262
Number of pages6
JournalSeminars in Ophthalmology
Volume29
Issue number5-6
DOIs
StatePublished - Sep 1 2014
Externally publishedYes

Fingerprint

Intravitreal Injections
Endophthalmitis
Vascular Endothelial Growth Factor A
Retinal Diseases
Risk Management
Macular Degeneration
Injections
Incidence
Therapeutics
Ophthalmologists

Keywords

  • Age-related macular degeneration (AMD)
  • Endophthalmitis
  • Intravitreal injection
  • Post-injection complications
  • Vascular endothelial growth factor (VEGF)

ASJC Scopus subject areas

  • Ophthalmology
  • Medicine(all)

Cite this

Complications of subspecialty ophthalmic care : Endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications. / Haddock, Luis; Ramsey, David J.; Young, Lucy H.

In: Seminars in Ophthalmology, Vol. 29, No. 5-6, 01.09.2014, p. 257-262.

Research output: Contribution to journalArticle

@article{5b62265efb3c4aba815c61fe5284edac,
title = "Complications of subspecialty ophthalmic care: Endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications",
abstract = "The use of medications directed against vascular endothelial growth factor (VEGF) signaling has revolutionized the treatment of age-related macular degeneration (AMD) and many other retinal diseases in the last decade. However, the rapidly increasing use of these agents has led to a rise in treatment-Associated complications. One of the most feared by patients and ophthalmologists is post-injection endophthalmitis, which can result in severe vision loss and, in rare cases, loss of the eye. The aim of this article is to review the incidence, clinical findings, risk factors, management, and visual outcomes in cases of endophthalmitis following intravitreal injections of anti-VEGF medications.",
keywords = "Age-related macular degeneration (AMD), Endophthalmitis, Intravitreal injection, Post-injection complications, Vascular endothelial growth factor (VEGF)",
author = "Luis Haddock and Ramsey, {David J.} and Young, {Lucy H.}",
year = "2014",
month = "9",
day = "1",
doi = "10.3109/08820538.2014.959616",
language = "English (US)",
volume = "29",
pages = "257--262",
journal = "Seminars in Ophthalmology",
issn = "0882-0538",
publisher = "Informa Healthcare",
number = "5-6",

}

TY - JOUR

T1 - Complications of subspecialty ophthalmic care

T2 - Endophthalmitis after intravitreal injections of anti-vascular endothelial growth factor medications

AU - Haddock, Luis

AU - Ramsey, David J.

AU - Young, Lucy H.

PY - 2014/9/1

Y1 - 2014/9/1

N2 - The use of medications directed against vascular endothelial growth factor (VEGF) signaling has revolutionized the treatment of age-related macular degeneration (AMD) and many other retinal diseases in the last decade. However, the rapidly increasing use of these agents has led to a rise in treatment-Associated complications. One of the most feared by patients and ophthalmologists is post-injection endophthalmitis, which can result in severe vision loss and, in rare cases, loss of the eye. The aim of this article is to review the incidence, clinical findings, risk factors, management, and visual outcomes in cases of endophthalmitis following intravitreal injections of anti-VEGF medications.

AB - The use of medications directed against vascular endothelial growth factor (VEGF) signaling has revolutionized the treatment of age-related macular degeneration (AMD) and many other retinal diseases in the last decade. However, the rapidly increasing use of these agents has led to a rise in treatment-Associated complications. One of the most feared by patients and ophthalmologists is post-injection endophthalmitis, which can result in severe vision loss and, in rare cases, loss of the eye. The aim of this article is to review the incidence, clinical findings, risk factors, management, and visual outcomes in cases of endophthalmitis following intravitreal injections of anti-VEGF medications.

KW - Age-related macular degeneration (AMD)

KW - Endophthalmitis

KW - Intravitreal injection

KW - Post-injection complications

KW - Vascular endothelial growth factor (VEGF)

UR - http://www.scopus.com/inward/record.url?scp=84912012247&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84912012247&partnerID=8YFLogxK

U2 - 10.3109/08820538.2014.959616

DO - 10.3109/08820538.2014.959616

M3 - Article

C2 - 25325851

AN - SCOPUS:84912012247

VL - 29

SP - 257

EP - 262

JO - Seminars in Ophthalmology

JF - Seminars in Ophthalmology

SN - 0882-0538

IS - 5-6

ER -